Apple and Samsung are the archrivals for the title of the world's top smart phone maker.

Olivia London

2018-06-25 12:43:00 Mon ET

Apple and Samsung are the archrivals for the title of the world's top smart phone maker. The recent patent lawsuit settlement between Apple and Samsung shows that the dollar sums are unlikely to significantly shrink either's bottom line. However, the case has caused a major impact on U.S. patent law. Both companies continue to impress smartphone consumers with AMOLED curvy touch screens, wireless charging capacities, facial recognition functions, and other high-tech features.

After a loss at trial, Samsung appealed to the U.S. Supreme Court. In December 2016, the court sided unanimously with Samsung's argument that a patent violator should not have to hand over the entire profit made from stolen design features if these features covered only specific portions of a smart product but not the entire object. When the case went back to the lower court for trial earlier in 2018, however, the jury sided with Apple's argument that Samsung's profits were wholly due to the design elements that directly violated Apple's prior patents. Because of the recent verdict, the legal settlement called for Samsung to make an additional $140 million payment to Apple on top of the prior $399 million payment that Samsung previously paid to Apple to compensate for iPhone-driven patent infringement.

The recent verdict marks the end of the 7-year-long patent dispute between Apple and Samsung. Due to hefty legal fees, neither side is a clear victor throughout the arduous battle.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Fed Chair Jerome Powell answers CBS News 60 Minutes questions about the recent U.S. economic outlook.

Dan Rochefort

2019-03-29 12:28:00 Friday ET

Fed Chair Jerome Powell answers CBS News 60 Minutes questions about the recent U.S. economic outlook.

Federal Reserve Chair Jerome Powell answers CBS News 60 Minutes questions about the recent U.S. economic outlook and interest rate cycle. Powell views the c

+See More

JPMorgan Chase CEO Jamie Dimon sees great potential for 10-year government bond yields to rise to 5%.

Olivia London

2018-08-05 12:34:00 Sunday ET

JPMorgan Chase CEO Jamie Dimon sees great potential for 10-year government bond yields to rise to 5%.

JPMorgan Chase CEO Jamie Dimon sees great potential for 10-year government bond yields to rise to 5% in contrast to the current 3% 10-year Treasury bond yie

+See More

Strategic managers envision lofty purposes to enjoy incremental consistent progress over time.

Jonah Whanau

2020-10-06 09:31:00 Tuesday ET

Strategic managers envision lofty purposes to enjoy incremental consistent progress over time.

Strategic managers envision lofty purposes to enjoy incremental consistent progress over time. Allison Rimm (2015)   The joy of strategy: a bu

+See More

Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018 with an incredible rags-to-riches life story.

John Fourier

2018-03-11 08:27:00 Sunday ET

Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018 with an incredible rags-to-riches life story.

At 89 years old, Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018. With a personal net worth of $35 billion, Li has an incredible ra

+See More

American China-specialists champion the key notion of *strategic engagement* with the Xi administration.

James Campbell

2018-12-11 10:34:06 Tuesday ET

American China-specialists champion the key notion of *strategic engagement* with the Xi administration.

Several eminent American China-specialists champion the key notion of *strategic engagement* with the Xi administration. From the Hoover Institution at Stan

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More